# EDGAR Filing Document

**Accession Number:** 0001759186
**File Stem:** 0000000000-23-001812
**Filing Date:** 2023-2
**Character Count:** 2566
**Document Hash:** be7ccc4c391a320570baceda7ea90eb6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001812.hdr.sgml**: 20230713

**ACCESSION NUMBER**: 0000000000-23-001812

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230223

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Coeptis Therapeutics Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001759186
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 981465952
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 105 BRADFORD ROAD, SUITE 420
- **CITY:** WEXFORD
- **STATE:** PA
- **ZIP:** 15090
- **BUSINESS PHONE:** 724-934-6467

**MAIL ADDRESS:**
- **STREET 1:** 105 BRADFORD ROAD, SUITE 420
- **CITY:** WEXFORD
- **STATE:** PA
- **ZIP:** 15090

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bull Horn Holdings Corp.
- **DATE OF NAME CHANGE:** 20181115
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001683168-23-000853

## Text-Extract

```

United States securities and exchange commission logo

                          February 23, 2023

       David Mehalick
       Chief Executive Officer
       Coeptis Therapeutics Holdings, Inc.
       105 Bradford Road, Suite 420
       Wexford Pennsylvania 15090

                                                        Re: Coeptis
Therapeutics Holdings, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed February 14,
2023
                                                            File No. 333-269782

       Dear David Mehalick:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Tim
Buchmiller at (202) 551-3635 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Denis Dufresne, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._